Skip to main content
. Author manuscript; available in PMC: 2022 Aug 18.
Published in final edited form as: Am Econ J Econ Policy. 2022 May;14(2):1–33. doi: 10.1257/pol.20200044

Figure 2:

Figure 2:

NOAC Prescription Volume over Time

Notes: For the three NOAC drugs we study, figure shows the average number of prescribed beneficiaries per quarter, per physician, in our sample. The average covers all physician-quarters in our sample, including those with zero prescriptions. The FDA first approved Pradaxa in 2010, Xarelto in 2011, and Eliquis in 2012. Data are from a 40 percent of Medicare Part D claims.